Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats
5-Amino-1MQ capsules contain a high-purity synthetic compound designed to inhibit nicotinamide N-methyltransferase (NNMT), playing a key role in metabolic regulation and energy homeostasis
10.1039/C9CP03767E 310

Key metabolic effects include: Enhanced lipolysis through activation of fat breakdown pathways independent of growth hormone receptors Suppressed lipogenesis reducing conversion of non-fat substrates into stored fat Increased fat oxidation and energy expenditure in multiple species models No adverse effects on insulin sensitivity or glucose metabolism, unlike full-length growth hormone Independence from IGF-1 Signaling A critical distinction of AOD-9604 is its lack of IGF-1 pathway activation: No measurable changes in serum IGF-1 levels in human clinical trials Absence of growth-promoting effects on tissues No impact on blood glucose regulation or insulin resistance Avoidance of typical growth hormone side effects including edema and tissue overgrowth Metabolic Pathway Modulation Research indicates AOD-9604 influences energy metabolism through multiple mechanisms: Increased whole-body fat oxidation rates in animal models Enhanced metabolic rate without stimulant-like effects Potential modulation of uncoupling proteins in adipose tissue Effects on lipid metabolism that persist beyond plasma clearance Critical Mechanistic Gap: Despite extensive research, the primary receptor target for AOD-9604 remains unidentified

Weight Loss Treatment : Improves overall health and wellness, aids in significant weight loss, and boosts confidence
"And it's not because of any magic it's because these are natural substances that our bodies make and are familiar with, so that's what gives them this incredible safety profile." The FDA, however, has publicly stated that there is not enough evidence from human clinical trials on the safety or efficacy of these drugs